High-resolution CE-MRA of Children's Hip Joint

High-resolution Contrast-enhanced Magnetic Mesonance Angiography of Children's Hip Joint

The goal of this observational study is to learn about the feasibility of enhanced three-dimensional water-selective cartilage (3D-WATSc) sequence in displaying the vessels of children's hip by magnetic resonance. The main questions it aims to answer are:

• Could the images of enhanced 3D-WATSc sequence show the healthy side hip joint vessels in children?
• Could the images of enhanced 3D-WATSc sequence show the vascular disease of the suffering side hip joint in children?

Participants with unilateral hip disease will undergo the magnetic resonance examination including enhanced 3D-WATSc sequence. The pelvic plain film and magnetic resonance images will be collected and analysed.

Researchers will compare the images of of the normal side with the images of the abnormal side to see if the enhanced 3D-WATSc sequence images could show the vascular disease of the suffering side hip joint in children?

Study Overview

• Status: Completed
• Conditions: Hip; Vessels; Anomaly; Magnetic Resonance; Three-dimensional Water-selective Cartilage (3D-WATSc)
• Intervention / Treatment: Other: Magnetic resonance examination

• Study Type: Observational
• Enrollment (Actual): 48

Contacts and Locations

Study Locations

• China
  • Chongqing
    • Chongqing, Chongqing, China, 400014
      • Children's Hospital of Chongqing Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 months to 14 years (Child)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Children with hip disease from 2021-2022 in Children's Hospital of Chongqing Medical University

Description

Inclusion Criteria:

• Children aged 6 months-14 years who are diagnosed as hip disease after screening by pediatric orthopedic surgeon in Children's Hospital of Chongqing Medical University during the study period. The hip disease contain developmental dysplasia of the hip, Perthes disease, infection of the hip, inflammation of the hip, fracture of the hip, and Meyer's dysplasia.

Exclusion Criteria:

• patients with bilateral hip joint disease; patients with claustrophobia;Patients with metal implants (such as pacemaker implantation)

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Normal hip joint; The normal side of patients with hip joint disease	Other: Magnetic resonance examination; the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence
Abnormal hip joint; The abnormal side of patients with hip joint disease	Other: Magnetic resonance examination; the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The medial circumflex femoral artery (MCFA) and lateral circumflex femoral artery (LCFA) of the bilateral hip joint	Morphology of the MCFA and LCFA of the bilateral hip joint	1 day (Magnetic resonance examination end time)
The branches of the MCFA and/or LCFA around the bilateral femoral neck	Morphology of MCFA and/or LCFA branches around the bilateral femoral neck	1 day (Magnetic resonance examination end time)
The vessels of secondary ossification center and/or cartilaginous vascular canal in bilateral femoral head	Morphology of the vessels and cartilaginous vascular canal in bilateral femoral head	1 day (Magnetic resonance examination end time)

Collaborators and Investigators

• Sponsor: Children's Hospital of Chongqing Medical University
• Investigators: Study Chair: Yuxi Su, M.D., Children's Hospital of Chongqing Medical University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2021
• Primary Completion (Actual): December 30, 2022
• Study Completion (Actual): January 31, 2023

Study Registration Dates

• First Submitted: February 23, 2023
• First Submitted That Met QC Criteria: March 3, 2023
• First Posted (Estimate): March 6, 2023

Study Record Updates

• Last Update Posted (Estimate): March 6, 2023
• Last Update Submitted That Met QC Criteria: March 3, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: CQMU-2023-2

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No